Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers
Open Access
- 5 August 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (8) , e0272034
Abstract
Inhaled antimicrobials enable high local concentrations where needed and, compared to orally administration, greatly reduce the potential for systemic side effects. In SARS-CoV-2 infections, hydroxychloroquine sulphate (HCQ) administered as dry powder via inhalation could be safer than oral HCQ allowing higher and therefore more effective pulmonary concentrations without dose limiting toxic effects. To assess the local tolerability, safety and pharmacokinetic parameters of HCQ inhalations in single ascending doses of 5, 10 and 20 mg using the Cyclops dry powder inhaler. Twelve healthy volunteers were included in the study. Local tolerability and safety were assessed by pulmonary function tests, electrocardiogram and recording adverse events. To estimate systemic exposure, serum samples were collected before and 0.5, 2 and 3.5 h after inhalation. Dry powder HCQ inhalations were well tolerated by the participants, except for transient bitter taste in all participants and minor coughing irritation. There was no significant change in QTc-interval or drop in FEV1 post inhalation. The serum HCQ concentration remained below 10 μg/L in all samples. Single doses of inhaled dry powder HCQ up to 20 mg are safe and well tolerated. Our data support that further studies with inhaled HCQ dry powder to evaluate pulmonary pharmacokinetics and efficacy are warranted.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosisEuropean Respiratory Review, 2013
- Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and ImidazoquinolinesThe Journal of Immunology, 2011
- Idiopathic Pulmonary Haemosiderosis in Childhood: A Good Response to Systemic Steroids, Inhaled Hydroxychloroquine and BudesonideArchivos de Bronconeumología, 2010
- Hemosiderosis pulmonar idiopática en la infancia: buena respuesta al tratamiento con esteroides sistémicos, hidroxicloroquina y budesonida inhaladaArchivos de Bronconeumología, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Dry powder inhalation of colistin in cystic fibrosis patients: A single dose pilot studyJournal of Cystic Fibrosis, 2007
- Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safetyPediatric Pulmonology, 2007
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2European Journal of Pharmaceutics and Biopharmaceutics, 2002
- Lung tissue volume estimated by simultaneous radiographic and helium dilution methods.Thorax, 1982